Navigation Links
Sleep Apnea Doubles Stroke Risk In Elderly

oke and noted that treatment for sleep apnea is becoming standard in reducing the risk of both heart attack and stroke. "People with sleep apnea are much more aggressively treated with respiratory aids during the night," he said.

People who are most likely to have sleep apnea are people who snore loudly, are overweight, have high blood pressure or have family history the disease. Excessive daytime sleeping is very common feature in sleep apnea.

Treatment for sleep apnea includes behavioral changes such as losing weight if person is overweight. Even a little weight loss can improve symptoms. Sleeping on the side, which helps keep the throat open, is another treatment for sleep apnea. Continuous positive airway pressure (CPAP) is the most common treatment for sleep apnea. A mouthpiece to the keep the airway open maybe helpful in people with mild sleep apnea. Some people with sleep apnea might benefit from surgery.


'"/>




Page: 1 2

Related medicine news :

1. Sleep apnoea increases post-operative risks
2. Sleep, snoring....stroke
3. Sleeping sickness - a silent killer
4. Deep Sleep Doesnt Increase Memory
5. Sleepwalking has genetic roots
6. Sleepy drivers increase road death toll
7. Sleep apnoea linked to surgical risks
8. Sleep disorders can have anomalistic sexual acts
9. Sleepwalking linked to a gene
10. Sleep Apnea Linked to Bed-Wetting in Kids
11. Race Affects Sleep in Children
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Sleep Apnea Doubles Stroke Risk Elderly

(Date:9/5/2008)...ashington, DCWomen with hormone-receptor positive,... years to help keep their cancer at bay, but when ..., treatment with chemotherapy becomes the only opt...Breast Cancer Symposiummay change this approach. ...re-sensitize" the tumor, allowing anti-hormonal dr...
(Date:9/4/2008)...INSTON-SALEM, N.C. Free drug samples provided to ...lly be costing uninsured patients more in the long...Wake Forest University Baptist Medical Center and ...the prescribing habits of more than 70 physicians ...ice in the months immediately before and after the...
(Date:9/4/2008)...erts develop sequence of instructions they say cou...DAY, Sept. 4 (HealthDay News) -- Vaccine safety ex... vaccines can receive vaccinations with close moni...porting in the September issue of Pediatrics , a ...s Center put forth a step-by-step set of instructi...
(Date:9/4/2008)...echnical and Naturals Pavilions are Sold-Out and S...Well-Represented, NEW YORK, Sept. 4 /PRNewswire/ ...cal equipment, naturals products, and sustainable,...po (http://www.hbaexpo.com ),September 9, 10, 11...ork.,Both the Technical and Naturals Pavilions at ...
Breaking Medicine News(10 mins):Health News:1 step back ... 2 steps forward 2Health News:Free drug samples may end up costing uninsured more 2Health News:Free drug samples may end up costing uninsured more 3Health News:Even Kids With Known Allergies Can Be Safely Vaccinated 2Health News:HBA Exhibit Floor Offers Global Resources to the Beauty and Personal Care Industry 2Health News:HBA Exhibit Floor Offers Global Resources to the Beauty and Personal Care Industry 3
...ettes syndromean inherited neurological disorder w...arn certain mental grammar skills much faster than...eurologists at Georgetown University Medical Cente..., the findings suggest that abnormalities in the b...
...found that two compounds from lobster shells, chit...roperties. The researchers said that the compounds...reat healing and antiseptic properties, as well as...eed and germination in seeds. Chitin is a very co...
...for its large-scale clinical study examining the p...n-prescription Zestra(R) Feminine Arousal Fluid fo... multi-center study, designed and managed by David...lacebo-controlled, double-blind, parallel design t...
...ustralian police finally announced that the Dr.Moh...ndia, was being charged with providing reckless s...one SIM card. His cousin Sabeel Ahmed 26, who wor...outheast of Liverpool, has been accused of having ...
Other Medicine News:Health News:Tourettes Syndrome in Children may also Result in Superior Learning Skills 2Health News:Lobster Shells Have Great Healing and Antiseptic Properties 2Health News:Study Shows Positive Results for Zestra(R) Feminine Arousal Fluid 2Health News:Three Doctors Charged So Far in the UK Bombing Case 2Health News:Three Doctors Charged So Far in the UK Bombing Case 3Health News:Three Doctors Charged So Far in the UK Bombing Case 4
(Date:9/3/2008)... that Multaq(R) (dronedarone) decreased the risk o...n or atrial flutter already adequatel... N.J., Sept. 3 /- The resul...ENA study were presented today at,the clinical tri...ology,congress 2008, in Munich, Germany. Previous ...
(Date:9/3/2008)...erations, Updates Zingo Launch Progress and Adlea ... Conference Call Today at 11:30 am ET,...-FirstCall/ -- Anesiva,Inc. (Nasdaq: ANSV ) anno...ations to focus on commercial and late-stage produ...pecialty pharmaceutical pain management,company. T...
(Date:9/3/2008)...uated in Repeat-Dosing Study in Subjects with ALS,... -- Sangamo,BioSciences, Inc. (Nasdaq: SGMO ) ann... trial (SB-509-801) to evaluate its drug, SB-509, ...motor-neuron disease for which there,are limited t...-509, is an injectable formulation of a plasmid,en...
(Date:9/2/2008).../- Forest Laboratories, Inc...day announced results from,two global Phase III st...nhaled anticholinergic for the treatment of patien...D). In both the ACCLAIM/COPD I&II,(AClidinium CLin...te to,Severe COPD Patients) studies, once-daily ac...
Breaking Medicine Technology:Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 2Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 5Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 2Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 3Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 4Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 6Gerber Scientific to Present at 10th Annual Needham Growth Stock Conference 9000 1Gerber Scientific to Present at 10th Annual Needham Growth Stock Conference 9000 2Transcript of Elizabeth Mazzocchi Press Conference 8996 1Transcript of Elizabeth Mazzocchi Press Conference 8996 2Transcript of Elizabeth Mazzocchi Press Conference 8996 3Transcript of Elizabeth Mazzocchi Press Conference 8996 4Transcript of Elizabeth Mazzocchi Press Conference 8996 5Exelixis Announces January 10 Webcast of Presentation at the 26th Annual JPMorgan Healthcare Conference 2415 1Oncolytics Biotech Inc Announces Filing of Phase 1 2 Clinical Trial with REOLYSIN 28R 29 2411 1Oncolytics Biotech Inc Announces Filing of Phase 1 2 Clinical Trial with REOLYSIN 28R 29 2411 2
...Donnelly, MT (ASCP) Contributing Editor , ,Qu...y to meeting the needs of doctors and patients by ...hods. Vendors of these systems can be a valuable r...tocols to help lab managers ensure that analytical...oping suitable QC materials for today,s laboratori...
...l S. Singer, M.D., Ph.D. Contributing Editor Harva...l for heart failure in African American patients h...espond differently to the same medication. This c...edications, and in many cases is due to individual...ics focuses on these issues, valuable new laborato...
Other Medicine Technology:New Quality Control Systems for Every Laboratory Application 2New Quality Control Systems for Every Laboratory Application 3Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy. 2Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy. 3
The OCULUS Pachycam is the first compact and portable non-contact pachymeter with built-in keratometer. The OCULUS Pachycam has automatic correction of the IOP (intra ocular pressure) in accordance
...ologies - plus wavefront analysis - in one easy-to...a single device, you can obtain refraction, cornea...vefront analysis. The 3-D Wave allows you to evalu...ve and cataract surgery screenings, evaluate posto...
...re sensor and continues to lead the way. PressureW...measures pressure, temperature and flow. With sign..., it also serves as your primary guidewire, as wel...gh-performance guidewire. , Intracoronary pressu...
...nd and MRI-guided vacuum assisted breast biopsies ...d, FDA-cleared ATEC system for a faster, safer, ea... biopsy. Its compassionate care at its best for th...eful for biopsy and diagnostic excision of breast ...
Medicine Products: